<SEC-DOCUMENT>0001394548-17-000003.txt : 20170119
<SEC-HEADER>0001394548-17-000003.hdr.sgml : 20170119
<ACCEPTANCE-DATETIME>20170119194410
ACCESSION NUMBER:		0001394548-17-000003
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20170117
FILED AS OF DATE:		20170119
DATE AS OF CHANGE:		20170119

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galena Biopharma, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239
		BUSINESS PHONE:		855 855 GALE

	MAIL ADDRESS:	
		STREET 1:		4640 SW MACADAM AVENUE
		STREET 2:		SUITE 270
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97239

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXI PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20110921

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Nejadnik Bijan
		CENTRAL INDEX KEY:			0001657705

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		17537252

	MAIL ADDRESS:	
		STREET 1:		80 TIPTOE LANE
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2017-01-17</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001390478</issuerCik>
        <issuerName>Galena Biopharma, Inc.</issuerName>
        <issuerTradingSymbol>GALE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001657705</rptOwnerCik>
            <rptOwnerName>Nejadnik Bijan</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O GALENA BIOPHARMA, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>2000 CROW CANYON PL., SUITE 380</rptOwnerStreet2>
            <rptOwnerCity>SAN RAMON</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94583</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Medical Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.81</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2017-01-17</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>30000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2027-01-17</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>30000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>30000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Granted pursuant to the Issuer's 2016 Incentive Plan.</footnote>
        <footnote id="F2">This stock option will vest in 16 equal, quarterly installments over four years, beginning three months from the date of grant, so long as the Reporting Person remains in the company's continuous employ through the vesting period.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>Bijan Nejadnik, M.D.</signatureName>
        <signatureDate>2017-01-19</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
